You are here: Industry Insights > ADC

News List

The Increasing ADC+CDMO Industry Collaboration Yefenghong/PharmaSources
April 19, 2023
Recently, the heat on ADC pipeline deals is around, and the deal sizes are kept refreshing.
Monthly News Review of PharmaSources (February) - Business Caicai/PharmaSources
March 14, 2023
On the business, Keymed Biosciences Inc. and Lepu Biopharma jointly announced an exclusive global licensing agreement with AstraZeneca for CMG901. In terms of the listing, Kelun Pharmaceutical's subsidiary Kelun Biotech intends to go public in Hong Kong.
Pharmaceutical Business Progress in China and Worldwide (April) PharmaSources
May 12, 2023
Progress in Pharmaceutical Business at Home and Abroad (April)
Antibody-Drug Conjugates - Lessons Learned Neeta Ratanghayra
May 20, 2022
Antibody-drug conjugates (ADCs) have made significant progress in tumor therapy and show a promising future.
Weekly Pharma News Review | PharmaSources.com (March 28 to April 1) PharmaSources.com
April 07, 2022
The failure of Phase III clinical trials targeting the popular target TIGIT monoclonal antibody has once again put tumor immunotherapy on the radar this week. The pharma news review of this week from March 28 to April 1 covers a total of 25 pieces of news
ADC vs PDC-- Status Quo of the R&D of ADC-PDC Drug in China and the World PharmaSources/zhulikou431
November 15, 2021
With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
A New Target in ADC: Nectin-4 PharmaSources/Yefenghong
September 14, 2021
Recently, the application for clinical trail of Mabwell's ADC drug (9MW2821) targeting Nectin-4 has been accepted by NMPA. It is the first time that domestic enterprise enters the IND stage with the same target drug.
Breaking News! The Second ADC Approved for Marketing in China PharmaSources/Xiaoyaowan
May 21, 2020
According to the NMPA website on May 13, the marketing application for Brentuximab Vedotin Injection filed by Takeda Pharmaceutical in China has been reviewed and approved, to become the second ADC approved for marketing in China.
Second ADC Therapeutic Drug Was Approved for Marketing in China CPhI.CN
May 14, 2020
Takeda Pharmaceutical's application of vebutuximab for injection has been approved and became the second ADC drug approved in the Chinese market.
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China PharmaSources
July 04, 2025
InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.